8-K: Apellis Pharmaceuticals Acquired by Biogen, Notes Modified

Apellis Pharmaceuticals has been acquired by Biogen Inc. through a merger, with convertible senior notes being modified to reflect the new ownership and terms.

Summary

• Apellis Pharmaceuticals, Inc. has been acquired by Biogen Inc. via a merger, effective May 14, 2026.
• The acquisition involved a tender offer where Biogen's subsidiary, Aspen Purchaser Sub, Inc., acquired shares for $41.00 cash plus a contingent value right (CVR) per share.
• Approximately 82.4% of Apellis shares were tendered in the offer.
• The merger was completed under Section 251(h) of the Delaware General Corporation Law, making Apellis a wholly owned subsidiary of Biogen.
• Existing Apellis convertible senior notes due 2026 have been modified through a First Supplemental Indenture.
• Noteholders can now convert their notes into a mix of cash and CVRs, with specific terms for conversions related to the merger event.
• The total aggregate amount paid in the acquisition is approximately $5.3 billion, excluding fees and potential CVR payments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, reflecting a successful acquisition at a premium and clear terms for stakeholders, though the contingent nature of CVRs introduces some uncertainty.

Positives

• Successful completion of the acquisition by Biogen, providing a clear outcome for shareholders.
• Shareholders received a cash payment of $41.00 per share plus a CVR, offering potential upside.
• The merger was completed efficiently, with a significant majority of shares tendered.
• Convertible noteholders have defined terms for conversion into cash and CVRs, providing certainty.
• Biogen estimates it would need approximately $582 million to cover maximum potential CVR payments, indicating a manageable contingent liability.

Negatives

• The company's status as an independent entity has ended.
• Shareholders who did not tender their shares may face a different process for receiving merger consideration.
• The value of CVRs is contingent on future performance, introducing uncertainty for that portion of the consideration.
• The delisting of Apellis Pharmaceuticals' common stock from Nasdaq signifies the end of its public trading as an independent company.

Risks

• There is no assurance that any of the CVR milestones will be achieved, meaning CVR holders may not receive the potential additional cash payments.
• The value of CVRs is subject to reduction for applicable tax withholding.
• Holders of convertible notes must carefully consider the timing of conversion to maximize their return, as different terms apply for standard conversions versus conversions during the Make-Whole Fundamental Change Period.
• The risk of untimely submission of repurchase notices or conversion instructions for noteholders.

Future Outlook

The future outlook for Apellis Pharmaceuticals is now tied to Biogen's strategic direction. The success of the CVRs depends on achieving specific annual net sales targets for SYFOVRE and related products in the coming years, with potential payments in 2027-2031.

Management Comments

• The Company may consolidate with, merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to another Person subject to the provisions of Section 11.01 of the Indenture, and the Merger complies with the provisions of Section 11.01 of the Indenture.
• Each share of common stock will be cancelled and converted into the right to receive $41.00 per share in cash, plus one contingent value right (CVR) per share.
• The CVR entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash upon the achievement of certain specified milestones.
• The consummation of the Merger constitutes a Merger Event, a Fundamental Change and a Make-Whole Fundamental Change under the Indenture.
• The Company represents and warrants that no Default or Event of Default shall have occurred or be continuing immediately after giving effect to the Merger Event.

Industry Context

StockSavvy.ai notes that this acquisition by Biogen, a major biotechnology company, reflects the ongoing trend of consolidation within the pharmaceutical and biotech sectors, particularly for companies with promising drug candidates or approved therapies like Apellis's SYFOVRE.

Comparison to Industry Standards

• The acquisition price of $41.00 per share plus a CVR of up to $4.00 per share represents a significant premium over recent trading prices, aligning with typical acquisition multiples for companies in the late-stage development or commercialization phase within the biopharmaceutical industry.
• The structure of the deal, including a cash component and a contingent value right, is a common mechanism used in pharmaceutical M&A to bridge valuation gaps between buyers and sellers, especially when future product performance is a key driver of value. Companies like Gilead Sciences (acquisition of Immunomedics) and Pfizer (acquisition of Seagen) have utilized similar structures.
• The terms for the convertible notes, including the modification to Reference Property and the Make-Whole Fundamental Change provisions, are standard within the industry for managing debt obligations in the context of a change of control event.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $41.00 cash and a CVR per share, with the option to not tender shares and receive merger consideration.
• Noteholders: Have options to convert notes into cash and CVRs or tender notes for repurchase, with specific terms and deadlines.
• Employees: Equity awards (options, RSUs, PSUs) were converted into cash payments and/or CVRs, with unvested awards converted into contingent rights subject to continued service.
• Creditors: The company's financing agreement was terminated and repaid, indicating no outstanding debt under that agreement post-merger.

Next Steps

• Apellis Pharmaceuticals will operate as a wholly owned subsidiary of Biogen.
• Biogen will proceed with integrating Apellis's operations and pipeline.
• Holders of Apellis convertible notes will need to decide whether to convert their notes or tender them for repurchase by the specified deadlines.
• The company's common stock will be delisted from Nasdaq, and its registration with the SEC will be terminated.
• CVR holders will await the achievement of specified net sales milestones for SYFOVRE and related products.

Key Dates

Recommendation

The acquisition by Biogen at a premium provides a clear exit for shareholders. For existing noteholders, the terms of conversion or repurchase are defined, but the value of CVRs is speculative. Given the completion of the acquisition and the defined terms for noteholders, a 'hold' recommendation is appropriate as the immediate price impact has occurred, and future value depends on Biogen's integration and CVR performance.

Keywords

Apellis Pharmaceuticals, Biogen Inc., Merger, Acquisition, Convertible Senior Notes, Contingent Value Rights, Tender Offer, SEC Filing